Evidence map›Paper›PMID 37581832›Full record

ArticleAdvances in experimental medicine and biology2023

Octenidine Versus Dispase Gels for Wound Healing After Cryosurgery Treatment in Patients with Basal Cell Carcinoma.

Nektarios Stratidakis, Anna Tagka, Styliani A Geronikolou, Efstathios Giannakopoulos, Antonios Panagiotopoulos, Evdokia Malachia, Andreas Vitsos, Evangelos Karalis, Paraskevas Dallas, Alexandros Stratigos and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in experimental medicine and biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 57% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Nektarios StratidakisDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece. nek.st@hotmail.co.uk.
Anna TagkaFirst Department of Dermatology and Venereology, "Andreas Syggros" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece. annatagka1@gmail.com.
Styliani A GeronikolouUniversity Research Institute of Maternal and Child Health and Precision Medicine, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Efstathios GiannakopoulosDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Antonios PanagiotopoulosFirst Department of Dermatology and Venereology, "Andreas Syggros" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Evdokia MalachiaFirst Department of Dermatology and Venereology, "Andreas Syggros" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Andreas VitsosDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Evangelos KaralisDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Paraskevas DallasDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
Alexandros StratigosFirst Department of Dermatology and Venereology, "Andreas Syggros" Hospital, National and Kapodistrian University of Athens, Medical School, Athens, Greece.
Michail RallisDivision of Pharmaceutical Technology, School of Pharmacy, National and Kapodistrian University of Athens, Athens, Greece.
National and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

For a specific group of patients with basal cell carcinoma (small, low risk), cryosurgery could be the suggested treatment, which results in the formation of an ulcer in the lesion area. The proteolytic enzymes' contribution to the wound healing is an ongoing research goal. Preclinical animal experiments in the Laboratory of the Pharmaceutical Technology Department of the National and Kapodistrian University of Athens have showed that a dose of 5 U/mL of dispase gel after the formation of tissue rashes, significantly promoted wound healing. Herein, a feasibility study in 16 patients enrolled by the First Department of Dermatology of Andreas Syggros Hospital was designed: 5 U/mL of dispase gel (once every 3 days) versus a drug reference containing octenidine (daily administration). The evaluation of the healing effect, safety, and tolerance was done on days 1 (cryosurgery), 2, 7, 21, and 60. The study end point was considered either the ulcer complete healing or the eighth week since treatment initiation. Wound healing was faster with dispase gel and hemoglobin reduced rapidly after the seventh day. Yet, hydration was higher in the control group. Our non-parametric analysis provides evidence that the dispase gel shows faster healing compared to the reference drug, in humans, meriting further investigation in larger human sample sizes before massive production of the product.

Indexed as

Basal Cell CarcinomaCryosurgerySkin NeoplasmsAnimalsEndopeptidasesGelsHumansIminesPyridinesUlcerWound HealingdispaseEndopeptidasesGelsIminesoctenidinePyridinesClinical trialDebridementDispaseEnzymesOctenidineSkin pharmacologyWound healing

Identifiers

PMID37581832
OpenAlexW4385827418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.